A new drug, lecanemab, has been approved by the US Food and Drug Administration “for treating Alzheimer’s disease.” The drug “slowed cognitive decline in patients with early Alzheimer’s disease.” According to Dr. Dennis Selkoe, Harvard Medical School professor, “For the first time in human history, we have an agent that can actually treat people with Alzheimer’s in a way that could slow their cognitive decline. We’ve never been able to say those words until the last few months.”